article thumbnail

Our Best of 2018- to Fuel Your Best 2019

Integrity Solutions

Here is some of our ‘Best of 2018’ content that can help fuel thoughts, discussions and strategies to make 2019 your best year yet. They have become increasingly more important- even becoming a competitive differentiator. We look forward to serving the world with integrity even more in 2019.

article thumbnail

Competition is on the horizon for costly narcolepsy treatments

pharmaphorum

But increased competition is on the horizon. Competition starts to heat up. Harmony Biosciences introduced Wakix to the market in 2019 as the first non-controlled substance for the treatment of narcolepsy. Furthermore, Molina stated Jazz “suppressed generic competition and raised the price of Xyrem 841% between 2007 and 2014.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Gilead, Teva prevail in high-stakes trial over HIV drug pay-for-delay claims

Fierce Pharma

Gilead and Teva have chalked up an important legal victory in a California court, defeating allegations that they created an anticompetitive scheme to delay generic competition to lucrative HIV tre | Gilead and Teva were accused of conspiring to keep HIV generics off the market in a 2019 lawsuit seeking $3.6 billion in damages.

article thumbnail

Adjusting Your Sales Approach- Questions Your Clients Have Right Now

Integrity Solutions

Those business plans were created in Q4 2019, a quarter that started with the continuation of the greatest period of economic expansion and stock market growth in history. What kinds of questions were company leaders asking during that last quarter of 2019 when those 2020 plans were being put together?

Sales 210
article thumbnail

Sorry, the Inflation Bill won’t lower healthcare costs

World of DTC Marketing

Increased provider consolidation has decreased individual market competition, in which lower prices, improved productivity, and innovation can occur. Without this competition, these near-monopolies have providers and insurers in a position where they can drive up their prices unopposed. According to another JAMA study, the U.S.

article thumbnail

Takeda plans 2026 CEO succession

European Pharmaceutical Review

She has a part of the Takeda Executive Team since 2019. Now is the right time to appoint my successor given our competitive growth outlook, new product launches expected from the second half of 2026 onwards and the anticipated retirement of some external independent directors in the coming years, explained Weber.

article thumbnail

Sustainability and technology advancement driving spectroscopy market

European Pharmaceutical Review

Their report ascertained that growth between 2019-2024 resulted from factors such as quality control demands, cost efficiency, rapid analysis, market competition, healthcare innovations. between 2019-2024 the process spectroscopy market] is expected to see growth due to key factors including industry 4.0 It will grow to $31.77